VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
STLN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
STLNStarling Oncology, Inc.
$3.40$362M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSTLNCash Flow

Starling Oncology, Inc. (STLN) Cash Flow Statement

7Y historyFree accessUpdated daily

Operating cash flow turned positive at $9.7M in Q2 2026, but this was driven by a $15.2M working capital benefit, and cumulative FCF over the last four quarters is -$9.9M, highlighting volatility.

Income StatementBalance SheetCash FlowRatios

STLN Cash Flow Statement

Annual statement

STLN Cash Flow Statement

Starling Oncology, Inc. (STLN) cash flow statement — 7-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations33.07M-24.59M-26.54M-36.31M-61.76M-32.68M508K3.62M
Operating CF Margin %--4.89%-6.75%-11.2%-24.46%-16.1%0.27%2.33%
Operating CF Growth %259.27%-26.92%41.2%-88.97%-6533.07%-85.95%-
Net Income-35.54M-60.61M-53.01M-83.07M152K-10.93M-14.32M-4.02M
Depreciation & Amortization9.96M6.94M6.29M5.87M4.41M3.34M3.18M2.94M
Stock-Based Compensation8.18M4.55M11.15M17.81M27.68M24.54M151K94.01K
Deferred Taxes0-32K0-76K-263K-1.24M-1.34M824.76K
Other Non-Cash Items39.54M23.23M2.12M20.79M-73.2M-33.9M11.85M326.93K
Working Capital Changes22.81M1.32M18.06M2.36M-20.54M-14.49M992K3.45M
Change in Receivables-8.47M-12.58M-5.77M-4.5M-19.66M-2.99M-6.76M-4.44M
Change in Inventory-20.85M-6.84M3.64M-4.38M-1.73M-1.84M-465K-1.13M
Change in Payables63.9M19.64M9.21M5.06M-6.19M2.92M3.76M5.53M
Cash from Investing-5.47M-3.07M46.21M62.64M-131.61M-12.15M-8.84M-1.2M
Capital Expenditures-6.22M-3.2M-3.79M-4.57M-5.53M-2.85M-1.19M-1.2M
CapEx % of Revenue1%0.64%0.96%1.41%2.19%1.4%0.64%0.78%
Acquisitions-5.02K00-4.46M-8.58M-9.11M-150K0
Investments--------
Other Investing0126K000-200K-7.5M0
Cash from Financing-9.83M11.56M-3.49M-6.85M92.21M154.01M11.89M-1.81K
Debt Issued (Net)-26K-20.04M-39K-101K109.94M-7.25M12.18M-1.81K
Equity Issued (Net)4.42M32.63M75K-1.02M-9M20M00
Dividends Paid00000000
Share Repurchases000-1.02M-9M000
Other Financing-14.23M-1.04M-3.53M-5.73M-8.74M141.26M-293K0
Net Change in Cash49.96M-16.1M16.18M19.48M-101.16M109.18M3.55M2.41M
Free Cash Flow26.86M-27.79M-30.33M-40.88M-67.28M-35.73M-686K2.41M
FCF Margin %4.33%-5.53%-7.71%-12.61%-26.65%-17.6%-0.37%1.55%
FCF Growth %--25.82%39.24%-88.33%-5108.02%-128.46%-
FCF per Share0.03-0.30-0.40-0.55-0.83-0.54-0.010.04
FCF Conversion (FCF/Net Income)-0.76x0.41x0.41x0.44x-406.29x2.99x-0.04x-0.90x
Interest Paid2.63M3.91M04.51M224K275K227K3.38K
Taxes Paid000403K150K1.73M207K61.27K

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Persistent operating losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Cash Conversion Diverges from Losses

In 2026Q2, TOI reported a net loss of $9.8M but generated $9.7M in operating cash flow, a swing driven by a $15.2M working capital benefit, per the latest quarterly report.

The positive operating cash flow in 2026Q2 appears to be largely a function of working capital timing rather than underlying earnings improvement, as net income remained negative. The OCF/NI ratio of -0.99 in 2026Q2 underscores the disconnect, with cash flow benefiting from collections or payables management. Investors should monitor whether this working capital tailwind reverses in subsequent quarters, as the prior two quarters showed negative operating cash flow despite similar loss levels.

FCF Turns Positive but Volatile

Free cash flow swung to $7.8M in 2026Q2 from -$3.3M in 2026Q1, yet the trailing four quarters show a cumulative FCF of -$9.9M, based on reported figures.

The positive FCF in 2026Q2 is a notable inflection, but it is inconsistent with the broader trend of negative FCF in most quarters over the past two years. The FCF margin of 4.8% in 2026Q2 is the first positive reading since 2024Q4, suggesting that revenue growth is beginning to translate into cash generation, albeit unevenly. However, the cumulative FCF remains negative, indicating that the company has not yet reached sustainable cash flow positivity.

Working Capital Swings Drive Cash Flow

Working capital changes contributed $15.2M to operating cash flow in 2026Q2, reversing a -$6.2M drag in 2025Q3, according to the cash flow statement.

The volatility in working capital changes is a dominant factor in TOI's cash flow, with swings of over $20M between quarters. This suggests that the company's cash flow is heavily influenced by the timing of receivables and payables, which may not be sustainable. The positive contribution in 2026Q2 could indicate improved collections or delayed payments, but it also raises questions about the quality of earnings, as the underlying net loss persists.

Minimal Capex Reflects Asset-Light Model

Capital expenditures averaged just 0.8% of revenue over the last four quarters, with 2026Q2 CapEx of $1.9M, per the latest financial data.

TOI's capital intensity is very low, which is consistent with a services-based healthcare model that does not require heavy investment in fixed assets. This means that the company's cash flow is less burdened by maintenance capex, allowing more of its operating cash flow to be available for other uses. However, the low capex also suggests limited investment in growth infrastructure, which may constrain future expansion if the company needs to scale its facilities.

No Capital Returns, Focus on Operations

TOI paid no dividends and made no buybacks in any of the last ten quarters, with all cash flow directed toward operations, as reported in the cash flow statements.

The absence of capital returns is typical for a company in a loss-making phase, as it conserves cash to fund operations and potential growth. The lack of acquisition activity, with only a small $126K outflow in 2025Q4, suggests that management is not pursuing aggressive M&A, which may be prudent given the cash constraints. Investors should monitor whether the company begins to return capital once it achieves sustained profitability.

Cumulative Losses Outpace Cash Burn

Over the last ten quarters, TOI's cumulative net loss of $137.6M exceeded its cumulative operating cash outflow of $48.5M, based on reported quarterly data.

The significant gap between cumulative net income and operating cash flow indicates that a large portion of the reported losses are non-cash in nature, primarily from depreciation, amortization, and stock-based compensation. This suggests that the company's cash burn is less severe than its accounting losses imply, which could provide some cushion. However, the persistent negative operating cash flow in most quarters still points to ongoing cash consumption that will require external funding if losses continue.

What Could Invalidate the Base Case

Despite the positive 2026Q2 operating cash flow, the reliance on working capital swings and persistent net losses suggest that cash generation may not be sustainable, per the cash flow data.

The cash flow statement obscures the underlying cash burn by showing a positive quarter driven by working capital timing, which may reverse. Additionally, the low capex and lack of investment could hinder growth, while the cumulative losses still exceed cash outflows, indicating that the company may need external funding. Investors should be cautious about extrapolating the 2026Q2 cash flow improvement without evidence of sustained operational profitability.

STLN — Frequently Asked Questions

Quick answers to the most common questions about buying STLN stock.

How much cash does Starling Oncology, Inc. (STLN) generate from operations?

Starling Oncology, Inc. (STLN) generated $-24.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Starling Oncology, Inc.'s free cash flow?

Starling Oncology, Inc. (STLN) reported negative free cash flow of $27.8M in 2025, indicating capital requirements exceeded cash from operations.

What is Starling Oncology, Inc.'s capital expenditure (CapEx)?

Starling Oncology, Inc. (STLN) spent $3.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.